个人简介
Dr. Nick Pliam is a Principal at Decheng Capital. He has been with the firm since its inception and Bay City Capital since 2005. Dr. Pliam is trained as a cell biologist and orthopedic surgeon, and has worked within, and as an advisor to, biopharmaceutical and medical technology companies. He is a founder of Guided Delivery Systems, a medical device company developing a minimally invasive technology for treatment of mitral valve regurgitation, and a founder of Pharmagenesis, a natural products pharmaceutical company. As an independent consultant and as managing director of a boutique investment banking firm, he has advised life science companies and investors (including Biomet, Devax, Hanwha Pharmaceutical, Marubeni Group, Micrus Endovascular, and Triage Medical) on financing transactions and strategy. He is an inventor with patents in medical devices and biopharmaceuticals. Dr. Pliam serves on the boards of directors of Nevro Corporation (NYSE: NVRO) and a former member of the board of IDev Technologies (acquired by Abbott Laboratories). He holds an MD from Dartmouth Medical School and a PhD in Endocrine Physiology from the University of California, San Francisco. Dr. Pliam completed his surgical training at UCSF and Stanford University. He completed his undergraduate degree in German literature from the University of California, Berkeley, and studied at Georg August Universitaet in Goettingen.
项目需求
投资行业偏好
医疗健康、生物科技
行业细分说明
具有革命性的技术的早期生命科学公司和增长阶段的医疗保健公司
意向运营时间
1年内, 1-3年, 3-5年, 5年以上
意向运营阶段
产品开发, 上线初期, 增长期
偏好投资轮次
天使轮, pre-A轮, A轮, B轮, C轮
偏好投资金额
50-100万, 100-500万, 500-1000万, 1000-5000万, 5000万以上
媒体报道